Valneva SE Logo

Valneva SE (VLA)

Euronext

Currency in EUR
2.92
+0.05 (+1.78%)

Closed

Aug 25, 2026

Day's Range

2.80
2.94

52 wk Range

2.03
5.33

Overview - VLA - Valneva SE

Key Statistics

Valuation

Enterprise Value

651.19M

P/E (Trailing)

‪70.64‬

P/E (Forward)

‪19.25‬

PEG Ratio

‪0.35‬

Price / Sales (TTM)

‪3.93‬

Price / Book

‪6.89‬

EV / EBITDA

‪-6.59‬

Profitability

Gross Margin

‪15.28%‬

Profit Margin

‪-110.29%‬

Operating Margin

‪-74.91%‬

Return on Assets

‪-16.68%‬

Return on Equity

‪-117.84%‬

Ownership

Shares Outstanding

173.75M

Float

157.26M

Held by Insiders

‪10.72%‬

Held by Institutions

‪24.41%‬

Price stats

Beta

‪1.34‬

50-Day Avg

‪2.33‬

200-Day Avg

‪3.21‬

Dividends

Payout Ratio

‪0.00%‬

Analyst Consensus

Buy

8 analysts

Average price target

‪€ 6.19‬

Peers - VLA - Valneva SE

Peer Comparison

Compared with companies in Biotechnology listed on Euronext.

Profile Summary - VLA - Valneva SE

About

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis;…

SectorHealthcare
IndustryBiotechnology
Employees700
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Stocks news

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.